Best Small Cap Healthcare Stocks Driving Medical Device Innovation

The medical device sector continues to attract significant investment attention as chronic conditions like cancer and diabetes fuel demand for advanced therapeutic solutions. In 2024, the FDA approved 30 innovative devices, reflecting the industry’s robust pipeline. Two critical trends are reshaping small cap healthcare stocks: the expansion of wearable medical technologies and the integration of artificial intelligence into diagnostic and treatment platforms. According to BCC Research analysis, the global medical device market is projected to expand from US$810.4 billion in 2024 to US$1.3 trillion by 2029, representing a CAGR of 9.8%. For investors seeking exposure to this growth trajectory, small cap healthcare stocks represent compelling opportunities within the NASDAQ exchange. This analysis examines the top performers in the medical device sector, focusing on companies with market capitalizations between US$50 million and US$500 million, based on data compiled in January 2025.

Delcath Systems (NASDAQ:DCTH): Pioneering Oncology-Focused Medical Innovation

Performance Metrics:

• 12-month return: 202.86%
• Market capitalization: US$405.43 million
• Share price: US$12.69

Delcath Systems represents one of the most dynamic small cap healthcare stocks in the oncology space, specializing in interventional oncology treatments for primary and metastatic liver cancers. The company’s proprietary Hepatic Delivery System (HDS) enables targeted high-dose chemotherapy directly to liver tumors while minimizing systemic exposure—a differentiated approach to cancer treatment.

The company’s commercial offerings include the FDA-approved Hepzato Kit in the United States, a combination drug-device product pairing the HDS with melphalan. In European markets, the HDS operates under the Chemostat Hepatic Delivery System designation as a standalone Class III medical device. Delcath’s 2024 momentum accelerated following favorable clinical outcomes. In Q2 2024, the company reported revenues of US$3.1 million, surging more than 416% compared to the prior-year period. Late August saw additional catalysts when independent research from Leipzig University validated the efficacy and safety of Delcath’s system for treating primary and secondary liver tumors.

Regulatory tailwinds continued through year-end when the FDA cleared Delcath’s investigational new drug application in December for a Phase 2 study evaluating Hepzato combined with standard-of-care therapies for liver-dominant metastatic colorectal cancer. The clearance authorized patient enrollment beginning in H2 2025. The company concluded 2024 with exceptional results, posting full-year revenues of US$37.2 million versus Q4 revenues of approximately US$15.1 million.

Sensus Healthcare (NASDAQ:SRTS): Non-Invasive Skin Cancer Solutions Among Top Small Cap Healthcare Stocks

Performance Metrics:

• 12-month return: 147.76%
• Market capitalization: US$108.01 million
• Share price: US$6.59

Sensus Healthcare exemplifies the innovation driving small cap healthcare stocks in the dermatology sector, offering non-invasive superficial radiotherapy (SRT and IG-SRT) for skin cancer and keloid treatment. The company’s patient-centric platform delivers superior efficacy compared to traditional approaches.

Early 2024 proved pivotal for Sensus’ market expansion. In May, the company announced the inaugural SRT-100 Vision (IG-SRT) system sale across Asia, followed by its first veterinary application sale in Israel. Accompanying these milestones, Q1 2024 revenues reached US$10.7 million, demonstrating robust 214% growth versus Q1 2023’s US$3.4 million. This performance catalyzed a substantial equity rally through mid-year.

Q3 2024 delivered continued momentum when Sensus disclosed revenues of US$8.8 million compared to US$3.9 million in the prior-year quarter. The stock reached its yearly zenith of US$8.94 per share in November, reflecting investor enthusiasm for the company’s expanding addressable market and accelerating commercial traction.

Pro-Dex (NASDAQ:PDEX): Surgical Instrumentation Powers Medical Device Growth

Performance Metrics:

• 12-month return: 118.55%
• Market capitalization: US$146.02 million
• Share price: US$44.80

Pro-Dex manufactures advanced battery-powered and electrical surgical instruments serving orthopedic, spine, craniomaxillofacial, and dental specialties. With clients spanning industry leaders like Medtronic, Smith & Nephew, and Arthrex, the company commands significant presence within institutional and surgical center procurement channels.

For much of 2024, Pro-Dex shares consolidated before accelerating sharply in the final quarter. Following the September release of fiscal 2024 results, the stock advanced 42% through early October. Q4 net sales (ended June 30) climbed 41% year-over-year to US$15 million, while fiscal 2024 revenues expanded 17% to US$53.8 million. November brought additional upside when the company disclosed fiscal Q1 2025 results (quarter ended September 30, 2024) showing 25% revenue growth to US$14.9 million. The stock surged 60% to US$49.55 per share, reflecting sustained operational execution within this competitive small cap healthcare sector.

AngioDynamics (NASDAQ:ANGO): Multi-Indication Medical Device Platform

Performance Metrics:

• 12-month return: 92.18%
• Market capitalization: US$477.29 million
• Share price: US$11.80

AngioDynamics operates as a global medical technology enterprise designing and manufacturing minimally invasive devices targeting vascular access, surgical intervention, peripheral vascular disease, and oncology applications. The company’s diversified portfolio positions it among the more established small cap healthcare stocks.

Mid-2024 brought significant regulatory wins when the company secured FDA 510(k) clearance and CE Marking for AlphaVac in pulmonary embolism treatment. CEO Jim Clemmer highlighted that these approvals opened substantial fast-growing markets, driving sequential Q4 AlphaVac revenue gains exceeding 68%. This clarity elevated the stock approximately 25% upon fiscal 2024 results disclosure.

December 2024 catalyzed another advance when the FDA granted 510(k) clearance for AngioDynamics’ NanoKnife System in prostate tissue ablation, generating a 31% rally to US$9.33. Most recently, the company’s fiscal Q2 2025 results (released January 2025) showed net sales of US$73 million, expanding 9.2% year-over-year. Shares reached US$12.94 in early January, validating investor confidence in the company’s clinical and commercial trajectory.

KORU Medical Systems (NASDAQ:KRMD): Infusion Technology Innovation in Small Cap Healthcare

Performance Metrics:

• 12-month return: 85.84%
• Market capitalization: US$186.56 million
• Share price: US$4.07

KORU Medical Systems specializes in mechanical infusion products, establishing market leadership with FDA-cleared syringe infusion technology since 1994. The portfolio centers on FREEDOM60 and FreedomEdge Syringe Infusion Drivers, precision flow rate tubing, and subcutaneous safety needle sets for diverse clinical applications.

KORU’s 2024 acceleration materialized in the final quarter. In late October, the company highlighted positive clinical preference data presented at the Drug Delivery Conference in Boston, demonstrating nursing preference for FreedomEdge systems versus manual administration in subcutaneous oncology infusion. November’s Q3 2024 results reinforced momentum, with net revenues reaching US$8.2 million, up 17% year-over-year.

December’s price appreciation toward US$4.40 per share reflected sustained enthusiasm for KORU’s value proposition within the specialized infusion market—a compelling example of how small cap healthcare stocks with differentiated technology and growing clinical adoption can deliver substantial investor returns.

Investment Landscape for Small Cap Healthcare Stocks

The five companies profiled above represent a cross-section of innovation within the medical device sector. Their 2024 performance—driven by FDA approvals, expanding clinical evidence, revenue acceleration, and emerging market opportunities—underscores why small cap healthcare stocks merit portfolio consideration. The projected 9.8% CAGR through 2029 ensures continued capital deployment toward breakthrough technologies addressing unmet clinical needs.

Investors evaluating small cap healthcare stocks should monitor regulatory milestones, quarterly revenue trajectories, and clinical validation alongside traditional valuation metrics. The sector’s dynamic nature rewards disciplined research and long-term conviction.

Follow @INN_LifeScience for ongoing medical device sector analysis and investment updates.

Important Disclosure: The author holds no direct investment interest in any company referenced herein. This analysis reflects market conditions as documented in early 2025 and should not be construed as investment advice.